What is claimed is:

1. A pharmaceutical composition comprising a formulation principle that stabilizes the amorphous form of Imatinib mesylate and amorphous Imatinib mesylate, optionally together with at least one pharmaceutically acceptable carrier, wherein the formulation principle is selected from solid dispersions, cyclodextrin complexes, and co-milling with selected excipients.

2. A pharmaceutical composition according to claim 1, wherein the formulation principle is a solid dispersion.

3. A pharmaceutical composition according to claim 1, wherein the formulation principle is a cyclodextrin complex.

4. The pharmaceutical composition according to any one of claims 1 to 3 which is a capsule.

5. The capsule according to claim 4 which contains between an amount of stabilized amorphous Imatinib mesylate which corresponds to 50 mg and 200 mg of Imatinib mesylate.

6. The capsule according to claim 5, wherein the shell contains gelatine.

7. The capsule according to claim 5, wherein the shell contains titanium dioxide.

8. The capsule according to claim 5, wherein the shell contains red iron oxide.

9. The capsule according to claim 5, wherein the ratio of weight of capsule fill to capsule shell is between about 100:25 and 100:50.

10. The capsule according to claim 5, wherein the ratio of weight of capsule fill to capsule shell is between 100:30 and 100:40.

11. The pharmaceutical composition according to any one of claims 1 to 3, which is a tablet.

12. The tablet according to claim 11 comprising an amount of stabilized amorphous Imatinib mesylate which corresponds to 100 mg, 400 mg or 800 mg of Imatinib mesylate.

Claims

1. A pharmaceutical composition comprising a formulation principle that stabilizes the amorphous form of Imatinib mesylate and amorphous Imatinib mesylate, optionally together with at least one pharmaceutically acceptable carrier, wherein the formulation principle is selected from (a) solid dispersions, wherein the solid dispersion comprises at least one further excipient, which is selected from cellulose derivatives, polyvinylpyrrolidone, polyethyleneglycols of various molecular weights, polyethylene-/polypropylene-/polyethylene-oxide block copolymers and polymethacrylates; and (b) dry co-milling with excipients selected from polyvinylpyrrolidone, cellulose derivatives, earth alkali metal silicas and silicates.

2. The pharmaceutical composition according to claim 1, wherein the formulation principle is a solid dispersion, wherein the solid dispersion comprises at least one further excipient, which is selected from cellulose derivatives, polyvinylpyrrolidone, polyethyleneglycols of various molecular weights, polyethylene-/polypropylene-/polyethylene-oxide block copolymers and polymethacrylates.

3. The pharmaceutical composition according to claim 1, wherein the formulation principle is dry co-milling with excipients selected from polyvinylpyrrolidone, cellulose derivatives, such as hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxypropylmethylcellulose acetate succinate (HPMC-AS), hydroxypropylcellulose phthalate (HPMC-P), or methylcellulose (MC), and earth alkali metal silicas and silicates.

4. The pharmaceutical composition according to claim 1 for use of the treatment of a disease selected from metastatic, inoperable GIST, advanced chronic myeloid leukemia, newly diagnosed chronic myeloid leukemia, pediatric Philadelphia chromosome-positive chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphocytic leukemia (ALL), glioblastoma multiforme, dermatofibrosarcoma protuberans (DFSP), hypereosinophilic sindrome (HES), and chronic myelomonocytic leucemia (CMML).

5. The use of a formulation principle which stabilizes the amorphous form of Imatinib mesylate as an intermediate for the preparation of a pharmaceutical composition comprising the amorphous form of Imatinib mesylate, wherein the formulation principle is selected from (a) solid dispersions wherein the solid dispersion comprises at least one further excipient, which is selected from cellulose derivatives, polyvinylpyrrolidone, polyethyleneglycols of various molecular weights, polyethylene-/polypropylene-/polyethylene-oxide block copolymers and polymethacrylates; and (b) dry co-milling with excipients selected from polyvinylpyrrolidone, cellulose derivatives, earth alkali metal silicas and silicates.